A randomized, double-blind, positive-controlled Phase III clinical trial to evaluate the efficacy and safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in population previously unvaccinated with COVID-19 vaccine and aged =18 years

Sinocelltech Ltd.0 个研究点目标入组 10,000 人开始时间: 2022年3月27日最近更新: 2023年5月29日

试验速览

阶段: 3 期
状态: 尚未招募
发起方: Sinocelltech Ltd.
入组人数: 10,000

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 19 Year(s) 至 44 Year(s)（—）
性别: All

入选标准

•1.Male or female aged =18 years old when signing ICF;
•2.Participants who were previously unvaccinated with any COVID-19 vaccine;
•3.The participant and/or his legal representative can sign written ICF, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;
•4.The participant and/or his legal representative have the ability to read, understand, and fill in record cards;
•5. Healthy participants or participants with pre-existing medical conditions who are in stable condition. The pre-existing medical conditions” include but not limited to hypertension, diabetes, Chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. A stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment;
•6.Fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the last dose of study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.

排除标准

•1.Previously diagnosed with COVID-19;
•2.A positive result of nucleic acid test or rapid antigen test for SARS-CoV-2 during the screening period;
•3.A positive result of anti-SARS-CoV-2 IgG antibodies during the screening period;
•4.Presence of fever within 3 days before the study vaccination;
•5.A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or other disease corresponding use of immunosuppressants;
•6.A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
•7.A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
•8.Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome [GBS], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;
•9.Long-term use of immunosuppressant therapy or immunomodulatory drugs for =14 days within the six months prior to enrollment. Whereas short-term (=14 days) use of oral, inhaled and topical steroids are allowed;
•10.Patients on antituberculosis therapy;
•11.Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia;
•12.Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
•13.Participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study;
•14.Participants who received other investigational drugs within 1 month before the study vaccination;
•15.Participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
•16.Participants received other drugs or vaccines used to prevent COVID-19;
•17.Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
•18.Those who donated blood or had blood loss (=450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
•19.Those who are pregnant or breast-feeding or plan to be pregnant during the study period;
•20.Those who plan to donate ovum or sperms during the study period;
•21.Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
•22.Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
•23.Those who are tested positive for HIV in terms of serology.

研究者

发起方

Sinocelltech Ltd.

相似试验

EUCTR2009-012787-14-NLBayer HealthCare AG690

进行中（未招募）

不适用

A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapyMetastatic Colorectal CarcinomaMedDRA version: 15.1Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2009-012787-14-HUBayer HealthCare AG690

进行中（未招募）

不适用

A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapyEnsayo en fase III, aleatorizado, doble ciego, controlado con placebo, de regorafenib con mejor tratamiento de soporte versus placebo con mejor tratamiento de soporte en pacientes con cancer colorectal metastásico que han progresado a tratamientos convencionales - CORRECTMetastatic Colorectal CarcinomaCáncer Colorectal MetastásicoMedDRA version: 12.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 12.1Level: LLTClassification code 10061451Term: Colorectal cancerMedDRA version: 12.1Level: LLTClassification code 10010036Term: Colorectal carcinomaMedDRA version: 12.1Level: LLTClassification code 10052358Term: Colorectal cancer metastatic

EUCTR2009-012787-14-ESBayer HealthCare AG690

进行中（未招募）

1 期

EUCTR2009-012787-14-FRBayer HealthCare AG760